OSU pathology home page

Daniel Jones, MD, PhD

Professor and Vice Chair

Daniel Jones, MD, PhD

Phone:

614-293-4993

E-mail:

Email Dr. Jones

Mailing Address:

2001 Polaris Parkway
Columbus, OH 43240

Biosketch

Dan Jones, MD, PhD is Professor of Pathology and Vice Chair, Division of Molecular Pathology. He also serves as Director of Molecular Pathology for the Ohio State University Comprehensive Cancer Center -- Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James). Dr. Jones earned his MD and PhD from Case Western Reserve University in Cleveland Ohio. He completed residency training and Hematopathology Fellowship training at Brigham and Women’s Hospital, Boston MA and did post-doctoral work at Harvard Medical School. He is boarded in Anatomic Pathology, Hematology and Molecular Genetic Pathology.

His research interests center on SARS-CoV-2 genomics, immune and host genomic predictors of COVID-19 disease severity, and defining critical genomic features in the progression and therapy resistance of lymphoid and myeloid leukemia. Projects underway include novel design of next-generation sequencing virus and host immune assays, bioinformatics strategies for characterization of uncommon sequence variants in cancer-associated genes and TP53 and PALB2 structure-function models.

Board Certifications

Molecular Genetic Pathology. Medical licenses in GA, MA, OH, TX, VA

Hematology, American Board of Pathology

Anatomic Pathology, American Board of Pathology

Academic and Medical Appointments

2015-Present Professor, Department of Pathology, The Ohio State University, Columbus Ohio

Professor (Adjunct), Department of Bioinformatics, The Ohio State University, Columbus Ohio

Director, Molecular Pathology, James Cancer Hospital & Solove Research Institute

Member, OSU Comprehensive Cancer Center and OSU Biomedical Sciences Graduate School

2009-Present Professor (Adjunct), School of Health Professions, University of Texas MD Anderson Cancer Center, Houston, TX

2009-2015 Medical Director, Quest Diagnostics (various roles), Nichols Institute, Chantilly, VA

1999-2009 Professor (Full/Associate/Assistant), Department of Hematopathology, University of Texas MD Anderson Cancer Center, Houston, TX

Education and Training

1997-1998 Post-doctoral fellowship, Harvard Medical School, Boston, MA (Laboratory of Timothy Springer)

1992-1996 Residency and Fellowship, Brigham and Women’s Hospital, Boston, MA

1986-1992 M.D., Ph.D., Medical Scientist Training Program, Case Western Reserve University, Cleveland, OH

Selected Publications

Search in PubMed

Books / Book Chapters:

  • Barnhill RL, Jones DM. Inflammatory Reactions in the Skin: Introduction to Microscopic Interpretation Approach to Diagnosis. In: Barnhill’s Dermatopathology. 4th Edition, McGraw-Hill, 6/2019.
  • Ho A., Jones D. Myeloproliferative Disorders and Myelodysplastic Syndromes. In: Molecular Diagnostics in Clinical Practice. 2nd Ed DGB Leonard Springer International, Switzerland, 2016
  • Zuckerberg L, Jones D. Non-lymphoid lesions of lymph nodes. In: Hematopathology. Eds E Jaffe, DA Arber, E Campo, NL Harris L Quintanilla-Martinez. Elsevier, Philadelphia, PA, 2016.
  • Jones D. Neoplastic Hematopathology: Experimental and Clinical Approaches. Humana Press/Springer: New York, 2013.
  • Jones D. Molecular Biology and Hematology. In: Wintrobe’s Clinical Hematology. 13th. Eds JP. Greer, DA Arber, BE. Glader, A List, T Means, Jr., GM Rodgers. Lippincott Williams & Wilkins: Philadelphia, PA, 2013.
  • Jones D, Han Z. Lymphoblastic Leukemia and Lymphoma: Molecular Diagnostics. In: Molecular Genetic Pathology. Ed(s) Cheng L, Zhang D, Eble JN. Springer: New York, 2013.

Publications:

  • Ai Y, Davis A, Jones D, Lemeshow S, Tu H, He F, Ru P, Pan X, Bohrerova Z, Lee J. Wastewater-based epidemiology for tracking COVID-19 trend and variants of concern in Ohio, United States. medRxiv. 2021 Jun 10.
  • Wang H, Jean S, Eltringham R, Madison, Tu H, Snyder P, Jones D, Leber A. Mutation-specific SARS-CoV-2 PCR Screen: Rapid and Accurate Detection of Variants of Concern and the Identification of a Newly Emerging Variant with Spike L452R Mutation. J Clin Microbiol 2021 May PMID: 34011523
  • Westerhoff M, Jones D, Hrycaj SM, Chan MP, Pantanowitz L, Tu H, Choi K, Greenson J, Lamps L. Gastrointestinal Pathology in Samples from Coronavirus Disease 2019 (COVID-19)-Positive Patients. Am J Pathol Lab Med 5/6/2021. PMID: 33961007
  • Ozga M, Blachly J, Grieselhuber N, Larkin K, Walker A, Bhatnagar B, Behbehani G, Long M, Haque T, Vasu S, Zhao W, Jones D, Byrd JC, Mims A, Saygin C. Type of prior genotoxic insult determines the genomic characteristics of therapy-related acute myeloid leukemia. Am J Hematol 2021/3/24. PMID: 33761147
  • Rogers KA, Andritsos LA, Wei L, McLaughlin EM, Ruppert EA, Anghelina M, Blachly JS, Call T, Carson WE, Chihara D, Dauki A, Guo L, Ivy SP, James LR, Jones D, Kreitman RJ, Lozanski G, Lucas DM, Ngankeu A, Phelps M, Ravandi F, Schiffer CW, Jones JA, Grever MR. Phase 2 study of ibrutinib in classic and variant hairy cell leukemia. Blood 2021 Mar 24. PMID: 33754642
  • Rogers KA, Thompson PA, Allan JN, Coleman M, Sharman JP, Cheson BD, Jones D, Izumi R, Frigault MM, Quah C, Raman RK, Wang MH, Kipps TJ. Phase 2 Study of Acalabrutinib in Ibrutinib-Intolerant Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia. Haematologica Mar 13 2021. PMID: 33730844.
  • Chen EV, Li S, Eisfeld A-K, Kuskin M, Mims A, Jones D, Antin JH, Cutler CS, Koreth J, Ho VT, Gooptu M, Romee R, El-Jawahri A, McAfee SL, DeLipill Z, Soiffer RJ, Chen Y-B, Fathi AT. Outcomes for patients with IDH-mutated acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation. Transplantation and Cellular Therapy. 2021 Jun;27(6):479.e1-479.e7. PMID: 33840625.
  • Huolin Tu, Matthew Avenarius, Laura Kubatko, Matthew Hunt, Xiaokang Pan, Peng Ru, Jason Garee, Keelie Thomas, Peter Mohler, Preeti Pancholi, Dan Jones Distinct Patterns of Emergence of SARS-CoV-2 Spike Variants including N501Y in Clinical Samples in Columbus Ohio. biorxiv 2021 Jan 13. PDF
  • Zhao W, Li Y, Yao C, Zhang G, Zhao KY, Chen W, Ru P, Pan X, Tu H, Jones D. Detection of Pathogenic Isoforms of IKZF1 in Leukemic Cell Lines and Acute Lymphoblastic Leukemia Samples: Identification of a Novel Truncated IKZF1 Transcript in SUP-B15. Cancers. 2020 Nov;12(11):3161. PMID: 33126432
  • Ren R, Krishna SG, Chen W, Frankel WL, Shen R, Zhao W, Avenarius MR, Garee J, Caruthers S, Jones D. Activation of the RAS pathway through uncommon BRAF mutations in mucinous pancreatic cysts without KRAS mutation. Mod Pathol. 2020 PMID: 32792597.
  • Chen W, Hampel H, Pearlman R, Jones D, Zhao W, Alsomali M, Knight D, Frankel WL. Unexpected Expression of Mismatch Repair Protein Is More Commonly Seen with Pathogenic Missense than Other Mutations in Lynch Syndrome. Human Pathology. 2020 Jul 8. PMID: 32652087
  • Hampel H, Pearlman R, de la Chapelle A, Pritchard C, Zhao W, Jones D, Yilmaz A, Chen W, Suarez A, Cosgrove C, Backes F, Copeland L, Fowler J, O’Malley D, Salani R, McElroy JP, Stanich P, Goodfellow P, Cohn DE. Double somatic mismatch repair gene pathogenic variants as common as Lynch syndrome among endometrial cancer patients. Gynecologic Oncology. 2020 Oct 21.
  • Voso MT, Larson RA, Prior TW, Marcucci G, Jones D, Krauter, J, Heuser M, Lavorgna A, Nomdedeu J, Geyer SM, Klisovic RB, Weis A, Sierra J, Sanz MA, Brandwein JM, de Witte TMM, Jansen JH, Niederwieser D, Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Amadori S, Cheng Y, Tiecke E, Du L, Ehrninger G, Thiede C, Döhner K, Döhner H, Stone RM, Bloomfield CD, Lo-Coco F. Midostaurin in patients with acute myeloid leukemia and FLT3-TKD mutations: a sub-analysis from the RATIFY trial. Blood Advances 2020 Oct 13;4(19):4945-54. PMID: 33049054
  • Park D, Bergin SM, Jones D, Ru P, Koivisto C, Jeon Y-J, Sizemore G M, Kladney R, Hadjis A, Shakya R, Ludwig T. Ablation of the Brca1-Palb2 interaction phenocopies Fanconi anemia in mice. Cancer Research July 30, 2020 doi: 10.1158/0008-547. PMID: 32732220
  • Kneuertz PJ, Carbone DP, D’Souza DM, Shilo K, M, Zhao W, Williams T, Jones D, Merritt RE. Prognostic Value and Therapeutic Implications of Comprehensive Molecular Testing for Resected Early Stage Lung Adenocarcinoma. Lung Cancer 2020 May;143:60-66. PMID: 32208298
  • Hu, EY, Blachly JS, Saygin C, Ozer HG, Workman SE, Lozanski A, Doong TJ, Chiang C-L, Bhat S, Rogers KA, Woyach JA, Coombes KR, Jones D, Muthusamy N, Lozanski G, Byrd J-C. LC-FACSeq is a method for detecting rare clones in leukemia. JCI Insight. 2020;5(12):e134973. PMID: 32554930
  • Döhner K, Thiede C, Jahn N, Panina E, Gambietz, Prior TW, Marcucci G, Jones D, Krauter, J, Heuser M, Lo-Coco F, Ottone T, Nomdedeu J, Mandrekar SJ, Huebner L, Laumann KM, Geyer SM, Klisovic RB, Wei A, Sierra J, Sanz MA, Brandwein JM, de Witte TMM, Jansen JH, Niederwieser D Appelbaum FR, Medeiros BC, Tallman MS, Schlenk RF, Ganser A, Serve H, Ehrninger G, Amadori S, Gathman I, Benner A, Pallaud C, Larson RA, Stone RM, Döhner H, Bloomfield CD. Prognostic and Predictive Impact of NPM1/FLT3-ITD Genotypes as Defined by 2017 European LeukemiaNet Risk Categorization from AML Patients Treated within the International RATIFY Study. Blood 2020 Jan;135(5):371-380. PMID: 31826241